Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Endo Pharmaceuticals  (Stock symbol: ENDP )

100 Endo Boulevard
Chadds Ford, PA 19317
Website Company Summary Management Team

Management: David Holveck (President);  Julie McHugh (COO);  Caroline Manogue (Executive VP);  Edward Sweeney (VP);  Roger Kimmel (Chairman of the Board);  Alan Levin (CFO)
Former Management Team:  Ivan Gergel
Business Description

Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer and central precocious puberty. Its portfolio of branded products includes Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar and Supprelin LA. The Company concentrates on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. During the year ended December 31, 2009, the branded products comprised approximately 91% of the Company's net sales. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus Pharmaceuticals, Inc.
Customer on 2  Companies

Partner on 1  Companies

Last Tweets


Last Mentions

Record updated: Sep 2010
Ownership: Public  
Stock Symbol: ENDP